Sandbox Reserved 899: Difference between revisions
From Proteopedia
Jump to navigationJump to search
New page: {{Sandbox_reserved_Karen_Glass_2020}}<!-- PLEASE ADD YOUR CONTENT BELOW HERE --> ==Your Heading Here (maybe something like 'Structure')== <StructureSection load='1stp' size='340' side='rig... |
No edit summary |
||
| Line 1: | Line 1: | ||
{{Sandbox_reserved_Karen_Glass_2020}}<!-- PLEASE ADD YOUR CONTENT BELOW HERE --> | {{Sandbox_reserved_Karen_Glass_2020}}<!-- PLEASE ADD YOUR CONTENT BELOW HERE --> | ||
== | ==CYP2C9 A477T (*30) variant with losartan== | ||
<StructureSection load='1stp' size='340' side='right' caption='Caption for this structure' scene=''> | <StructureSection load='1stp' size='340' side='right' caption='Caption for this structure' scene=''> | ||
This is a default text for your page ''''''. Click above on '''edit this page''' to modify. Be careful with the < and > signs. | This is a default text for your page ''''''. Click above on '''edit this page''' to modify. Be careful with the < and > signs. | ||
Revision as of 21:53, 3 March 2020
| This Sandbox is Reserved from Jan 13 through July 31, 2020 for use in the course Protein Structure in Drug Discovery taught by Karen C. Glass at the ACPHS, Colchester, United States. This reservation includes Sandbox Reserved 895 through Sandbox Reserved 901. |
To get started:
More help: Help:Editing |
CYP2C9 A477T (*30) variant with losartan
| ||||||||||||